Brainstorm Cell Therapeutics Inc (BCLI)
0.54
-0.04
(-6.57%)
USD |
NASDAQ |
May 24, 13:28
Brainstorm Cell Therapeutics Enterprise Value: 39.73M for May 23, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 23, 2024 | 39.73M |
| May 22, 2024 | 39.31M |
| May 21, 2024 | 42.67M |
| May 20, 2024 | 38.96M |
| May 17, 2024 | 35.67M |
| May 16, 2024 | 35.38M |
| May 15, 2024 | 33.14M |
| May 14, 2024 | 34.27M |
| May 13, 2024 | 37.63M |
| May 10, 2024 | 30.43M |
| May 09, 2024 | 31.19M |
| May 08, 2024 | 28.65M |
| May 07, 2024 | 24.41M |
| May 06, 2024 | 24.82M |
| May 03, 2024 | 25.23M |
| May 02, 2024 | 26.48M |
| May 01, 2024 | 28.96M |
| April 30, 2024 | 25.06M |
| April 29, 2024 | 36.16M |
| April 26, 2024 | 35.81M |
| April 25, 2024 | 35.63M |
| April 24, 2024 | 36.52M |
| April 23, 2024 | 35.16M |
| April 22, 2024 | 36.19M |
| April 19, 2024 | 35.63M |
| Date | Value |
|---|---|
| April 18, 2024 | 34.42M |
| April 17, 2024 | 36.24M |
| April 16, 2024 | 35.30M |
| April 15, 2024 | 36.78M |
| April 12, 2024 | 39.19M |
| April 11, 2024 | 38.72M |
| April 10, 2024 | 40.39M |
| April 09, 2024 | 39.09M |
| April 08, 2024 | 49.19M |
| April 05, 2024 | 43.78M |
| April 04, 2024 | 45.42M |
| April 03, 2024 | 46.40M |
| April 02, 2024 | 48.43M |
| April 01, 2024 | 49.87M |
| March 28, 2024 | 37.29M |
| March 27, 2024 | 39.72M |
| March 26, 2024 | 43.67M |
| March 25, 2024 | 43.33M |
| March 22, 2024 | 37.54M |
| March 21, 2024 | 31.41M |
| March 20, 2024 | 33.25M |
| March 19, 2024 | 22.94M |
| March 18, 2024 | 21.08M |
| March 15, 2024 | 21.38M |
| March 14, 2024 | 21.09M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
5.560M
Minimum
Oct 24 2023
530.89M
Maximum
Oct 08 2020
114.06M
Average
89.60M
Median
Jun 10 2022
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 5.965M |
| Palatin Technologies Inc | 22.10M |
| iBio Inc | 27.49M |
| Theriva Biologics Inc | -9.587M |
| Oragenics Inc | 9.416M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.401M |
| Total Expenses (Quarterly) | 2.474M |
| EPS Diluted (Quarterly) | -0.05 |
| Earnings Yield | -59.26% |